Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Burdock Root

NICE Approves Use Of Lenalidomide In Patients With Multiple Myeloma Who Have Received Two Or More Previous Therapies
Around 2000 multiple myeloma sufferers in the UK could have their lives extended by around three months after a decision by The UK National Institute for Health and Clinical Excellence (NICE) to approve lenalidomide in those patients who have received two or more previous therapies-provided that the cost of cycles beyond the 26th cycle of treatment are met by the drug manufacturer. A summary of the NICE decision is published in a Special Report Online First and in the July edition of The Lancet Oncology.
generic viagra online
Trinity Biotech Receives FDA Approval For Destiny Max In The USA
Trinity Biotech plc (NASDAQ: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, announced the FDA approval and US launch of its high throughput haemostasis analyzer, the Destiny Max.
News of the day
Groups Want NJ To Restore Immigrant Outreach Funds
"Immigrant and health-care advocacy groups" are calling on New Jersey to "restore $1 million in funding that has been eliminated in the latest round of budget tightening," the AP/Philadelphia Inquirer reports. "The money was earmarked for community-outreach efforts to educate legal immigrants on available state health programs." A report released yesterday by Rutgers University concluded that "New Jersey"s percentage of uninsured immigrant children is higher than the national average, and the state has a poor track record of making sure those children receive health coverage."
Public Health

REGiMMUNE Presents Enhanced Efficacy Data In Preclinical Transplantation Models

Data presented at the 2009 American Transplant Congress REGiMMUNE Corporation has announced that its lead product candidate RGI-2001, in combination with a low-dose of Sirolimus, demonstrated enhanced efficacy in transplantation tolerance induction in models of skin transplantation and acute Graft-versus-Host disease (GvHD). This data was presented in a poster titled "Donor-Specific Tolerance Induction by a Liposomal Formulation of KRN7000 (RGI-2001) Alone and in Combination with Low-Dose Sirolimus" at the 2009 American Transplant Congress being held in Boston. "We are extremely pleased to present this data," stated Haru Morita, President and Chief Executive Officer of REGiMMUNE. "The study not only demonstrated the efficacy of RGI-2001 in solid organ transplants; it showed the potential of RGI-2001 to induce antigen-specific transplantation tolerance, which is considered a holy grail in transplantation." KRN7000, a synthetic derivative of alpha-galactosylceramide, is a small molecule that potently activates natural killer T (NKT) cells. RGI-2001 is a proprietary liposomal formulation of KRN7000. RGI-2001 monotherapy has shown to induce antigen-specific immune suppression by inducing regulatory T cells (Tregs). Tregs are believed to play a central role in inducing and maintaining immune tolerance. The study was designed to evaluate the efficacy of RGI-2001 in combination with Sirolimus in transplantation tolerance induction in mouse models. Study Results Pharmacological induction of alloantigen-specific tolerance is expected to provide significant clinical benefits in organ transplantation and bone marrow transplantation. The REGiMMUNE study concluded that the addition of a subtherapeutic dose of Sirolimus enhanced the efficacy of RGI-2001 in both models. The combination treatment significantly prolonged the survival of grafts in the skin transplant model over Sirolimus single treatment. Likewise, GvHD mortality was reduced by the combination treatment. In addition, the combination of RGI-2001 with low-dose Sirolimus significantly enhanced Treg induction. The results indicate the potential of RGI-2001 to be a key component of a novel tolerance induction regimen, avoiding the use of calcineurin inhibitors that are not only associated with high toxicity but suppress Treg activity. The finding suggests the possibility to develop a pharmacological approach to induce long-term transplant tolerance by promoting the body"s intrinsic tolerogenic pathways using RGI-2001. RGI-2001 is in late preclinical development and REGiMMUNE plans to file an Investigational New Drug (IND) for the prevention of acute GvHD associated with bone marrow transplantation later this year. Debra Bannister REGiMMUNE


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009